Market Newsdesk

SAN DIEGO, Nov. 19, 2020 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the performance and application of its Saphyr system for optical genome mapping are being showcased at the Annual Meeting of the Association for Molecular Pathology (AMP), being held virtually at amp20.amp.org from November 16-20. AMP is widely recognized as the preeminent scientific society dedicated to advancing the clinical practice, science and excellence of molecular and genomic laboratory medicine. With over 2,500 members in over 50 countries working in the field of molecular pathology, its annual meeting is considered the prime event for presenting advances and technological innovations in molecular diagnostics to pathologists, laboratory directors and clinical professionals.

The Annual Meeting of AMP carries an educational component that teaches pathologists and laboratory professionals about novel and emerging methods in molecular pathology. For the first time at the meeting this year, Bionano optical genome mapping was taught as a technique in molecular pathology in the Get AMPed! Virtual Course on testing modalities for genome structure analysis along with current standard of care methods such as karyotyping, FISH and microarray analysis.

In other sections of the conference, the application of the Saphyr system in a growing number of clinical applications is being showcased in a Corporate Workshop presented by Bionano and in a poster presentation. These events cover the recent progress in applying Saphyr to an expanding array of diseases, including repeat expansion disorders such as amyotrophic lateral sclerosis (ALS), Fragile-X syndrome, Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and a variety of other complex genetic disorders and heme malignancies.

Below is a listing of presentations at AMP 2020 featuring the use of Bionano’s optical genome mapping technology:

Updates and Case Studies in Molecular Pathology – Get


AMPed


! Virtual Course


Sunday, November 15, 2020 – 12:30 pm – 12:55 pm
Testing Modalities to Look at Genome Structure: Conventional Cytogenetics, FISH and Chromosomal Microarray Analysis
Yassmine Akkari, Ph.D., Legacy Health

AMP Corporate Workshop


November 16-20, 2020 – On-Demand
Next Generation Cytogenomics: High Resolution Structural Variation Detection by Optical Mapping
Alex Hastie, Ph.D., Vice President Clinical Affairs, Bionano Genomics

AMP 2020 Abstracts/Posters
–
On-Demand

TT3
4:
Optical Mapping Enables High-Throughput Analysis of Pathogenic Repeats

Ernest Lam, Ph.D., Senior Manager, Bioinformatics, Bionano Genomics
Repetitive elements are abundant and diverse in the human genome. They are also genetically unstable. Repeat expansions and contractions could impact protein structure and gene regulation. They underlie disorders such as facioscapulohumeral muscular dystrophy (FSHD) and amyotrophic lateral sclerosis (ALS). However, sequence analysis of these regions can be challenging. Clinical laboratories often rely on Southern blotting, which is labor-intensive and typically requires radioactive staining. Optical mapping with Bionano Genome Imaging provides an alternative high-throughput workflow that overcomes these limitations.

About Bionano Genomics

Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the presentations identified in this press release; the effectiveness and utility of Bionano’s technology in basic genetic research and clinical settings, including its clinical applications with respect to genetic disorders and heme malignancies; the capabilities of Bionano’s technology in comparison to other standard of care methods; and Bionano’s strategic plans. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]

Investor Relations Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
[email protected]

Media Contact:

Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
[email protected]

SAN DIEGO, Nov. 19, 2020 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leading National Security Solutions provider and industry-leading provider of high-performance, jet-powered unmanned aerial systems, announced today that it has delivered the 100^th production BQM-177A Subsonic Aerial Target (SSAT), nearing completion of its third and final Low Rate Initial Production (LRIP) contract.

Captain Molly Boron, Program Manager, Aerial Targets Program (PMA-208) stated, “I am proud to accept delivery of this 100^th aircraft on behalf of the U.S. Navy. The government-industry team of PMA-208 and Kratos Unmanned Aerial Systems (KUAS) has worked hard to deliver this capable target on time and on budget. 2020 has been a successful year despite COVID-19 challenges. We are completing LRIP III deliveries, have awarded the $29.2M Full Rate Production (FRP) Lot 1 contract on 29 September for 35 more BQM-177A SSATs, and are currently activating the operational site at Pacific Missile Range Facility (PMRF) in Kauai, HI. The combined PMA-208 and KUAS team is positioned to successfully achieve Full Operational Capability this fiscal year. We are delivering targets and support equipment to Atlantic Target & Marine Operations at Dam Neck, VA in anticipation of their transition to the BQM-177A this winter. We will complete the transition of this capability when the PMRF Detachment Far East site in Okinawa, Japan is activated with a ship-launch capability. The delivery of the 100^th target signifies a well-performing production line but also represents an incredible amount of teamwork enabling relevant anti-ship cruise missile training and combat system testing for the Fleet.”

Steve Fendley,
President of
Kratos Unmanned Systems Division, said, “The delivery of this 100^th aircraft represents the very hard work of many dedicated Navy and KUAS engineering, production, program, logistics, financial, and supply chain professionals. We stand shoulder-to-shoulder with our Navy customers as we activate additional sites and operationalize this capability around the world. The KUAS team remains committed to the mission of providing the most capable systems and realistic training possible to the warfighters.”

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information, please visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2019, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:

Yolanda White
858-812-7302 Direct

Investor Information:

877-934-4687
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e99ef0b3-35bf-4e74-92e5-b517c28ec9af

PHILADELPHIA and IRVINE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) — Hill International (NYSE:HIL) (Hill), the global leader in managing construction risk, announced today that it has been selected by the Board of Directors of the Los Angeles County Metropolitan Transportation Authority (Metro) and awarded a contract to provide construction support services for a significant improvement project on U.S. Interstate 5 (I-5).

In cooperation with Caltrans District 7, Metro is undertaking a project to improve road conditions of the I-5 as it passes through northern Los Angeles County in the area of Santa Clarita—an approximately 40-minute drive from downtown Los Angeles. The work will extend from the I-5/SR 14 interchange to Parker Road in Santa Clarita and Los Angeles County. This nearly 14-mile stretch covers other major interchanges including State Route 126 and Magic Mountain Parkway. Improvements include the addition of high-occupancy vehicle lanes along the median of I-5, the creation of and maintenance of existing truck lanes, and the construction of auxiliary lanes between on-ramps and subsequent off-ramps. The project will also involve intelligent transportation system improvements, including traffic count stations, closed-circuit television cameras, and ramp metering. These improvements will enable the road to handle more traffic at peak hours and provide a safer and faster commute for the residents of northern Los Angeles County.

“In Los Angeles, traffic affects our quality of life substantially,” says Hill Vice President and project Senior Construction Engineer David Tiberi, PE. “By undertaking infrastructure improvement projects, Metro is saving time and money for the millions of people who live and work in Los Angeles County. Our local team is ready to support Metro’s project with high-quality construction support services and help deliver the work on time and under budget.”

As the construction support services consultant, Hill will assist Metro staff in providing construction management oversight for the project. Hill’s support services will begin in the contract procurement phase, continue through pre-construction activities and construction, and culminate in the construction contract closeout. Our professionals will support Metro during inspections, provide administrative support, and offer various technical assistance through the lifecycle of the project. Hill will also help manage and confirm compliance with contract requirements and government regulations.

“We’re proud to continue offering our services to Metro—a client we are fortunate to have supported on many transportation projects over the years,” says Hill Chief Executive Officer Raouf Ghali. “Our teams have also accrued valuable experience supporting other I-5 improvement projects with different government agencies, such as the Orange County Transportation Authority. These projects are critical to keeping Southern California moving and we look forward to bringing the industry-leading services our teams regularly provide throughout the region to Metro’s I-5 improvement project.”

About Hill International

Hill International, with approximately 2,700 professionals in 69 offices worldwide, provides program management, project management, construction management, and other consulting services to clients in a variety of market sectors. Engineering News-Record magazine recently ranked Hill as the eighth-largest construction management firm in the United States. For more information on Hill, please visit our website at www.hillintl.com.

Forward Looking Statements

Certain statements contained herein may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is our intent that any such statements be protected by the safe harbor created thereby. Except for historical information, the matters set forth herein including, but not limited to, any statements of belief or intent, any statements concerning our plans, strategies, and objectives for future operations are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although we believe that the expectations, estimates, and assumptions reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Important factors that could cause our actual results to differ materially from estimates or projections contained in our forward-looking statements are set forth in the Risk Factors section and elsewhere in the reports we have filed with the Securities and Exchange Commission, including that unfavorable global economic conditions may adversely impact our business, our backlog may not be fully realized as revenue, and our expenses may be higher than anticipated. We do not intend, and undertake no obligation, to update any forward-looking statement.

Hill International, Inc.

Elizabeth J. Zipf, LEED AP BD+C
Senior Vice President
(215) 309-7707
[email protected]

The Equity Group
, Inc.

Devin Sullivan
Senior Vice President
(212) 836-9608
[email protected]

Investors with losses are encouraged to contact the firm before November 20, 2020; click


here


to submit trade information

LOS ANGELES, Nov. 19, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of GoHealth, Inc. (NASDAQ: GOCO) investors that acquired shares in connection with GoHealth’s July 2020 initial public offering. Investors have until November 20, 2020 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

On July 15, 2019, GoHealth sold approximately 43.5 million shares of stock in its initial public stock offering (the “IPO”), at $21.00 per share raising almost $914 million in new capital.

On August 19, 2020, in GoHealth’s first quarterly earnings report following the IPO, announced that it had incurred a net loss of $22.9 million in it’s 2nd Quarter after reporting net income of $15.3 million in the prior-year period.

Shares of GoHealth’s stock are presently trading at almost 50% below its recent IPO price, at $14.26 per share.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

GridGain
Ranked
380

^th

Fastest Growing Company
Nationally
with
253
Percent Revenue Growth Over the Past Four Years
,
Rank
ed
73

^rd

in the San Francisco Bay Area

FOSTER CITY, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) — GridGain Systems, provider of enterprise-grade in-memory computing solutions based on Apache^® Ignite^®, today announced it ranked number 380 on the Deloitte 2020 Technology Fast 500™, a list of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. GridGain grew 253 percent over the past four years and was ranked 73^rd among San Francisco Bay Area companies.

“As companies accelerate their digital transformations, our industry-leading in-memory computing platform provides the speed, scale and ease of deployment needed to rapidly build a high performance, data-driven IT infrastructure,” said Abe Kleinfeld, President and CEO of GridGain Systems. “We’re honored to achieve this ranking for the third consecutive year, and it reflects GridGain’s continued ability to innovate, execute and deliver the solutions our customers depend on to run their businesses.”

“For more than 25 years, we’ve been honoring companies that define the cutting edge, and this year’s Technology Fast 500 list is proof positive that technology — from software and digital media platforms, to biotech — truly does permeate so many facets of our lives,” said Paul Silverglate, vice chairman, Deloitte LLP and U.S. technology sector leader. “We congratulate this year’s winners, especially during a time when innovation is needed more than ever to address the monumental challenges posed by the pandemic.”

The GridGain In-Memory Computing Platform

The GridGain in-memory computing platform provides in-memory speed and massive scalability for data-intensive applications. It can power a digital integration hub (or smart operational datastore, smart data hub or API platform) for building highly performant applications that aggregate and process defined subsets of data from multiple on-premises and cloud-based systems, including data warehouses, data lakes, on-premises business applications, SaaS applications and streaming data feeds. GridGain also enables hybrid transactional/analytical processing (HTAP) to run pre-defined analytics on operational databases without impacting system performance. GridGain solutions require no rip-and-replace of existing databases and can be deployed on-premises, on a public or private cloud, or in a hybrid environment. GridGain can also function as a full-featured, standalone in-memory database or as a multi-tier computing environment that spans in-memory and disk-based data, allowing users to make a tradeoff between application performance and infrastructure cost. Based on the open source Apache Ignite project, GridGain offers up to a 1,000x improvement in performance versus disk-based databases when used as an in-memory data grid or in-memory database. GridGain supports data processing APIs such as ANSI-99 SQL, key-value, compute, machine learning and more, and supports ACID transactions – all at in-memory speeds.

To learn more about the GridGain in-memory computing platform:  

• Read the “Introducing the GridGain In-Memory Computing Platform” white paper
• Read the “Powering Your Digital Transformation with a Digital Integration Hub” application note
• Gain knowledge from the GridGain Developer Portal and GridGain webinars
• See how GridGain helps CTOs & CIOs, Architects, Business Decision Makers and Developers
• Read GridGain customer success stories and industry use cases

About GridGain Systems

GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache^® Ignite^®. Common use cases for the GridGain platform include application acceleration and as a digital integration hub for real-time data access across data sources and applications. GridGain solutions are used by global enterprises in financial services, software, e-commerce, retail, online business services, healthcare, telecom, transportation and other major sectors, with a client list that includes ING, Raymond James, American Express, Société Générale, Finastra, IHS Markit, ServiceNow, Marketo, RingCentral, American Airlines, Agilent, and UnitedHealthcare. GridGain delivers unprecedented speed, massive scalability, and real-time data access for both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache^® Hadoop^®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory database. For more information, visit gridgain.com.

CONTACT:

Terry Erisman
GridGain Systems
[email protected]
(650) 241-2281

GridGain is a trademark or registered trademark of GridGain Systems, Inc. Apache, Apache Hadoop, Hadoop, Apache Ignite, Ignite, Apache Kafka, Kafka, Apache Spark, and Spark are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the pricing of its public offering of 7,500,000 ordinary shares at a public offering price of $10.00 per share. The gross proceeds from the public offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and other offering expenses. The underwriters have a 30-day option to purchase from the Company up to an additional 1,125,000 ordinary shares at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds of this offering to support the commercialization of plinabulin, continued clinical and pre-clinical development and for general corporate purposes. The offering is expected to close on November 23, 2020, subject to satisfaction of customary closing conditions.

BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the offering and H.C. Wainwright & Co. is acting as co-manager for the offering.

The offering is being made pursuant to the Company’s existing shelf registration statement, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 3, 2020 and became effective on November 12, 2020. The offering of these securities is being made only by means of a prospectus and a related prospectus supplement, which will be filed with the SEC. Copies of the prospectus and prospectus supplement related to this offering may be obtained, when available, from: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at [email protected], Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by calling (877) 821-7388, or by emailing [email protected] or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at (888) 474 0200, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares or any other securities, nor shall there be any sale of such shares or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About BeyondSpring

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring’s lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Certain of the statements made in this press release are forward-looking, such as those, among others, relating to BeyondSpring’s expectations regarding the completion of the offering. No assurance can be given that the offering discussed above will be consummated, or that the net proceeds of the offering will be used as indicated. Consummation of the offering and the application of the net proceeds of the offering are subject to numerous possible events, factors and conditions, many of which are beyond the control of the Company and not all of which are known to it, including, without limitation, market conditions and those described under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, as updated by those risk factors included in the Company’s subsequent filings under the Securities Exchange Act of 1934, as amended, which can be accessed at the SEC’s website at www.sec.gov. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet its expectations regarding the potential safety, the ultimate efficacy or clinical utility of its product candidates, increased competition in the market, the impact of widespread health developments, including the recent COVID-19 pandemic, and the responses thereto, which could materially and adversely affect, among other things, enrollment of patients in the Company’s clinical trials and its expected timeline for data readouts of its clinical trials and certain regulatory filings for its product candidates, unexpected changes to estimates of its expenses, future revenues and capital requirements, and other risks described in BeyondSpring’s most recent Form 20-F on file with the SEC. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACT:

Investor Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
[email protected]

Media Contact:

Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
[email protected]

BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, and Eyal Attar, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.

The pre-recorded fireside chat will be accessible for a limited time beginning November 23, 2020 in the Investors section of Aprea Therapeutics’ website at www.aprea.com.

About A
prea
Therapeutics, Inc.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement

Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and projected cash position. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies, risks associated with the coronavirus pandemic and the other risks set forth in our filings with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Source: Aprea Therapeutics, Inc.

Corporate Contacts:

Scott M. Coiante
Sr. Vice President and Chief Financial Officer
617-463-9385

Gregory A. Korbel
Vice President of Business Development
617-463-9385

– Business Combination to Bring PublicaLeading Online Platform to Play the Lottery –

–
Lottery.com Grew Revenue at a CAGR
o
f
279
% from 2016-2019
;
Significant Industry Tailwinds Poised to
Further
Accelerate Growth
–

NEW YORK and AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) — Trident Acquisitions Corp. (NASDAQ: TDACU, TDAC, TDACW) (“Trident”), announced that it has entered into a binding letter of intent (“LOI”) for a business combination transaction with Lottery.com, which would result in Lottery.com (the “Company”) becoming a publicly traded company on The Nasdaq Stock Market.

Founded in 2015, Lottery.com is a leading online platform to play the lottery from your phone, offering official state-sanctioned lottery games, like Powerball, Mega-Millions and state games, in the U.S. and around the world. Lottery.com is also the world’s largest provider of lottery data to over 400 digital publishers, including hundreds of digital newspapers, television and news sites, and major digital publishers such as Google, Verizon/Yahoo, Amazon’s Alexa devices and more. Its digital lottery platform provides valuable lottery-related data, such as current and previous winning numbers, jackpots and draw dates, jackpot analysis and more, covering almost 600 lottery games in 38 countries in real time.

Lottery.com has been a pioneer in the lottery industry, working closely with state regulators to advance the industry into the digital age. Through its online platform, Lottery.com is providing official lottery games increased revenues and better regulatory capabilities by developing innovative blockchain technology, while also capturing untapped market share, including Millennial players. The platform is currently live in the Company’s home state of Texas and nine other U.S. states with expansion plans into more than 20 U.S. states and several new countries in 2021. Additionally, the Company is the only lottery platform authorized to sell Powerball tickets in 148 countries, with rapid international expansion plans for next year. Lottery.com’s ultimate vision is becoming a global lottery marketplace.

From 2016 to 2019, Lottery.com grew revenues at a compounded annual growth rate of 279%, and the Company anticipates accelerating that growth with the capital infusion from this potential transaction.

“Lottery.com has developed an innovative platform that is revolutionizing the lottery industry and bringing it into the digital age,” said Marat Rosenberg, Chairman of Trident. “The Company has developed a world-class safe and secure mobile lottery platform that provides users the ability to play official lottery games right from their phone. Lottery.com is developing blockchain technology to maintain an accurate ledger of each transaction, significantly curtailing the ability for fraudulent activity. With a track record of substantial revenue growth and user base expansion in a relatively short period of time, we believe that Lottery.com has the potential to cement its place as the leading online platform to play the lottery worldwide. We also believe we can replicate our recent success story of bringing Triterras, Inc. public through a business combination with Netfin Acquisition Corp. As an experienced SPAC team with a track record in the blockchain-enabled online platform space, we look forward to introducing the story of Lottery.com to the public market.”

Co-founder and CEO of Lottery.com, Tony DiMatteo, commented: “Since the inception of Lottery.com, it was our aim to cooperatively transform a legacy industry with innovative technologies and capture significant market share of a large population of smartphone-using potential customers. We have already been successful in our mission, accelerating revenue growth each year, expanding our footprint and making the lottery much more accessible to modern consumers through an easy-to-use and secure mobile application and core technology. As we look to further capitalize on current trends with more consumers shopping from home and interacting through mobile applications than ever before, we believe the business combination with Trident will provide us ample capital to accelerate our growth and enter our next stage as a public company.”

Lottery.com is supported by a strong advisory board and notable investors within the venture capital, gaming and entertainment industries, including:

• Jason Robins, CEO of DraftKings
• Peter Diamandis, Chairman of XPRIZE Foundation
• Ben Narasin, Venture Partner of NEA
• Paraag Marathe, President of 49ers Enterprises
• Matthew Le Merle, Co-founder and Managing Partner of Fifth Era and Keiretsu Capital
• Jamie Gold, The Poker Philanthropist

Transaction Overview

The proposed transaction contemplates that Lottery.com’s stockholders will roll 100% of their equity into the business combination with no minimum cash requirement.

The parties intend to execute a definitive agreement, and currently anticipate closing the business combination in first quarter of 2021. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all. Any transaction would be subject to the approval of the two companies’ boards, regulatory and shareholder approvals as well as other customary conditions.

About Trident Acquisitions Corp.

Trident Acquisitions Corp. is a special purpose acquisition company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. Trident’s securities are quoted on the Nasdaq stock exchange under the ticker symbols TDACU, TDAC and TDACW. For more information, visit tridentacquisitions.com.

About
Lottery.com

Lottery.com is an Austin, TX-based company enabling consumers to play state-sanctioned lottery games from their home or on the go. The Company works closely with state regulators to advance the lottery industry, providing increased revenues and better regulatory capabilities, while capturing untapped market share, including millennial players. Lottery.com is also gamifying charitable giving to fundamentally change how non-profits engage with their donors and raise funds. Through their WinTogether.org platform, they offer charitable donation sweepstakes to incentivize donors to take action by offering once in a lifetime experiences and large cash prizes.

Forward Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this presentation, regarding the proposed business combination between Trident and Lottery.com, Trident and Lottery.com’s ability to consummate the transactions, the benefits of the transactions and the combined company’s future financial performance, as well as the combined company’s strategy, future operations, estimated financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, Trident and Lottery.com disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Trident and Lottery.com caution you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of either Trident or Lottery.com. In addition, Trident cautions you that the forward-looking statements contained in this press release are subject to the following factors: (i) the occurrence of any event, change or other circumstances that could delay the business combination or give rise to the termination of the agreements related thereto; (ii) the outcome of any legal proceedings that may be instituted against Trident or Lottery.com following announcement of the transactions; (iii) the inability to complete the business combination due to the failure to obtain approval of the shareholders of Trident, or other conditions to closing in the merger agreement; (iv) the risk that the proposed business combination disrupts Lottery.com’s current plans and operations as a result of the announcement of the transactions; (v) Lottery.com’s ability to realize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of Lottery.com to grow and manage growth profitably following the business combination; (vi) costs related to the business combination; (vii) risks related to the rollout of Lottery.com’s business and the timing of expected business milestones; (viii) Lottery.com’s dependence on obtaining and maintaining lottery retail licenses or consummating partnership agreements in various markets; (ix) Lottery.com’s ability to maintain effective internal controls over financial reporting, including the remediation of identified material weaknesses in internal control over financial reporting relating to segregation of duties with respect to, and access controls to, its financial record keeping system, and Lottery.com’s accounting staffing levels; (x) the effects of competition on Lottery.com’s future business; (xi) risks related to Lottery.com’s dependence on its intellectual property and the risk that Lottery.com’s technology could have undetected defects or errors; (xii) changes in applicable laws or regulations; (xiii) the COVID-19 pandemic and its effect directly on Lottery.com and the economy generally; (xiv) risks related to disruption of management time from ongoing business operations due to the proposed business combination; (xv) risks relating to privacy and data protection laws, privacy or data breaches, or the loss of data; and (xvi) the possibility that Lottery.com may be adversely affected by other economic, business, and/or competitive factors. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Trident has filed and will file from time to time with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Trident’s SEC filings are available publicly on the SEC’s website at www.sec.gov.

Important Information and Where to Find it

In connection with the proposed business combination, Trident, expects to file a preliminary proxy statement (the “Proxy Statement”) with the SEC for the solicitation of proxies from Trident’s shareholders. Additionally, Trident and Lottery.com Holdings will file other relevant materials with the SEC in connection with the business combination. Copies may be obtained free of charge at the SEC’s web site at www.sec.gov. A definitive proxy statement will be mailed to Trident shareholders as of a record date to be established for voting on the proposed business combination. Investors and security holders of Trident are urged to read the proxy statement and the other relevant materials when they become available before making any voting decision with respect to the proposed business combination because they will contain important information about the business combination and the parties to the business combination. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation

Trident and its directors and officers may be deemed participants in the solicitation of proxies of Trident’s shareholders in connection with the proposed business combination. Lottery.com and its officers and directors may also be deemed participants in such solicitation. Security holders may obtain more detailed information regarding the names, affiliations and interests of certain of Trident’s executive officers and directors in the solicitation by reading Trident’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and the Proxy Statement and other relevant materials filed with the SEC in connection with the business combination when they become available. Information concerning the interests of Trident’s participants in the solicitation, which may, in some cases, be different than those of their stockholders generally, will be set forth in the proxy statement relating to the business combination when it becomes available.

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

Investor Relations Contact:

Gateway Investor Relations
Cody Slach
(949) 574-3860
[email protected]

Trident
Contact:
Vadim Komissarov
CEO
(646) 229-7549
[email protected]

Lottery.com Contact:

Cody Billingsley
(520) 250-3369
[email protected]

SAN FRANCISCO, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) — Kenna Security, the enterprise leader in risk-based vulnerability management has won the CISO Choice Award for Vulnerability Management from Security Current. A first of its kind vendor recognition, the CISO Choice Awards reflect a selection of solutions by leading CISOs based on real-world experiences.

Kenna Security was selected as the winner of the Vulnerability Management category for its leading risk-based vulnerability management solution. Kenna.VM enables security and IT teams to understand which vulnerabilities pose the most risk, so they can efficiently prioritize and patch these dangerous security gaps. Kenna.VM puts risk in context, enabling organizations to improve security while saving time and resources.

“CISOs, like the panel of judges, understand the challenge organizations are facing in managing the sheer number of cybersecurity vulnerabilities they face on a daily basis,” said Ed Bellis, founder and CTO of Kenna Security. “We pioneered a way forward through risk-based vulnerability management. This award recognizes our leadership in helping organizations better understand risk as they work to stay secure.”

Honoring security vendors of all types, sizes and maturity levels, the CISO Choice Awards recognizes differentiated solutions valuable to the CISO and enterprise from security solution providers worldwide. The CISO Choice Awards are part of Security Current and the exclusive CISOs Connect membership knowledge-sharing community, providing CISO and cybersecurity leaders across industries invaluable information on vendors in today’s constantly evolving security environment.

You can watch the CISO Board of Judges Winners’ Video here.

About Kenna Security

Kenna Security is the enterprise leader in risk-based vulnerability management. The Kenna Security Platform enables organizations to work cross-functionally to determine and remediate cyber risks. It leverages machine learning and data science to track and predict real-world exploitations, empowering security teams to focus on what matters most. Headquartered in San Francisco, Kenna serves nearly every major vertical and counts CVS, KPMG, and many Fortune 100 companies among its customers.

Media & Analyst Contact:

Matt McLoughlin

Gregory FCA for Kenna Security

Phone: 609-385-2058

Email: [email protected]

SAN DIEGO, Nov. 19, 2020 (GLOBE NEWSWIRE) — Cue Health Inc. (Cue) announced today that, as of November 9, the U.S. Department of Health and Human Services (HHS) began deploying its molecular, point-of-care COVID-19 Tests to five states, including Alaska, Florida, Louisiana, New Jersey, and Texas. The tests will be utilized for quick confirmatory testing of positives and suspicious negatives in high-concern populations and congregate care settings, such as nursing homes, long-term care, assisted living facilities, and veterans’ homes. The tests will also be used internally at the Department of Defense (DOD).

“Our mission as a company has always been to provide patients and healthcare providers with access to actionable, accurate health data in real-time,” said Ayub Khattak, Founder & CEO of Cue. “The deployment of Cue’s point-of-care COVID-19 Test will not only increase molecular testing capacity in critical locations but will also help protect the health of the most vulnerable populations by providing real-time results in about 20 minutes.”

“The Cue Health testing system will undoubtedly be a valuable addition to our testing ecosystem,” noted HHS Assistant Secretary for Health ADM Brett Giroir, M.D. “Having a highly specific and sensitive POC molecular test could dramatically improve infection control at nursing homes and other institutional settings.”

The Cue Health Monitoring Systems and the Cue COVID-19 Tests will be delivered to a single designated location. The governors’ offices, working closely with their state health departments, will determine allocations and further deployment to local and regional facilities based on their respective and evolving needs. Based upon the concept of use and the different situations for access to care, the distribution will be adjusted. For example, Alaska will receive 200 Monitoring Systems and 9,000 test cartridges due to the remote nature of access to testing. Meanwhile, Florida, Louisiana, New Jersey, and Texas will each receive 100 Monitoring Systems and 4,500 test cartridges. This deployment of tests to the pilot participants is the initial deployment, with tens of thousands more tests to be manufactured and deployed in the next weeks. In each of the states, Cue plans to provide immediate onboarding and training support for facilities that receive its test.

Cue’s COVID-19 Test is a portable, compact, easy-to-use, molecular test that detects the RNA of SARS-CoV-2 using a nasal swab (the Cue Sample Wand) taken from the lower part of the nose by a trained healthcare provider. Specimen collection and execution of the test is simple, requires minimal training, and is completely automated in its process of sample to result. Cue’s molecular assay and connected platform, which provide results to a mobile smart device in about 20 minutes, is an efficient solution for frequent, fast, reliable testing at point-of-care.

The Cue COVID-19 Test received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) on June 10, 2020. The test is performed by a healthcare professional under the supervision of an Authorized Laboratory operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. 

On October 13, 2020, the HHS and DOD announced an award to Cue that will enable the company to expand its industrial base and U.S. production capacity to deliver six million COVID-19 tests and 30,000 Monitoring Systems to the U.S. Government by March 2021, to support the domestic pandemic response. This effort is being led by the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in coordination with the DOD Joint Acquisition Task Force (JATF) and funded through the HHS Office of the Assistant Secretary for Health, to enable and support domestic production of critical medical resources.

About Cue Health

Cue Health Inc. (“Cue”) is an ISO 13485-certified company founded by Ayub Khattak and Clint Sever focused on developing and manufacturing professional and consumer medical diagnostic products that can be used in clinical or at-home settings. Cue’s mission is to create tools that empower healthcare providers and consumers by increasing their access to actionable health data. Cue’s first product, the Cue Health Monitoring System with the Cue COVID-19 Test Cartridge, is a platform that provides diagnostic information to clinicians and patients seeking to benefit from a connected healthcare delivery ecosystem. The company is based in San Diego, CA. For more information visit www.cuehealth.com

This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by authorized laboratories; this test has been authorized only for the detection of nucleic acid from SARSCoV-2, not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Media Contact:

Amanda Lazaro
[email protected]